top of page

Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of MCI and Alzhermer's DS

JAMA Neurol.Published online June 22, 2020. doi:10.1001/jamaneurol.2020.18disease

Key Points

Question Does intranasally delivered insulin provide a feasible and effective treatment for adults with mild cognitive impairment or Alzheimer disease dementia?

Findings In this randomized clinical trial of 289 adults with mild cognitive impairment or Alzheimer disease dementia, no cognitive or functional benefits were observed with intranasal insulin treatment compared with placebo over a 12-month period in the primary analyses. The study execution and interpretation of results were complicated by issues with the intranasal delivery device.

Meaning The results of this study suggest that further investigation is needed with intranasal delivery devices that have been reported to increase insulin levels in the central nervous system, which might better determine the therapeutic benefit of intranasal insulin for the treatment of persons with mild cognitive impairment and Alzheimer disease dementia.

1 view0 comments

Recent Posts

See All


bottom of page